Evidence for tumour necrosis factor/cachectin production in cancer. 1987

F Balkwill, and R Osborne, and F Burke, and S Naylor, and D Talbot, and H Durbin, and J Tavernier, and W Fiers
Imperial Cancer Research Fund Laboratories, London.

Labile tumour-necrosis-factor-like (TNF) activity was detected by means of an enzyme-linked immunosorbent assay in 50% of 226 freshly obtained serum samples from cancer patients with active disease. In contrast, only 3% of 32 samples from normal subjects and 18% of 39 samples from cancer patients with no clinically evident disease were positive for this factor, with low levels of activity. Greater proportions of serum samples from patients with ovarian or oat-cell carcinoma were positive (69% and 63%) than those from patients with lymphoma (26%). RNA preparations from peripheral-blood mononuclear cells and solid tumours were probed with TNF complementary DNA; evidence of TNF messenger RNA was found in 8 of 11 samples of peripheral-blood mononuclear cells from cancer patients, but only 1 of 8 normal subjects, and in 2 of 6 colorectal tumours. As yet the inducing stimulus and the clinical significance of TNF production in cancer are not understood.

UI MeSH Term Description Entries
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

F Balkwill, and R Osborne, and F Burke, and S Naylor, and D Talbot, and H Durbin, and J Tavernier, and W Fiers
November 1985, Lancet (London, England),
F Balkwill, and R Osborne, and F Burke, and S Naylor, and D Talbot, and H Durbin, and J Tavernier, and W Fiers
January 1988, International journal of dermatology,
F Balkwill, and R Osborne, and F Burke, and S Naylor, and D Talbot, and H Durbin, and J Tavernier, and W Fiers
May 1989, Lancet (London, England),
F Balkwill, and R Osborne, and F Burke, and S Naylor, and D Talbot, and H Durbin, and J Tavernier, and W Fiers
August 1988, Clinical and experimental immunology,
F Balkwill, and R Osborne, and F Burke, and S Naylor, and D Talbot, and H Durbin, and J Tavernier, and W Fiers
January 1989, Cancer surveys,
F Balkwill, and R Osborne, and F Burke, and S Naylor, and D Talbot, and H Durbin, and J Tavernier, and W Fiers
April 1995, Journal of the Egyptian Society of Parasitology,
F Balkwill, and R Osborne, and F Burke, and S Naylor, and D Talbot, and H Durbin, and J Tavernier, and W Fiers
May 1989, Journal of internal medicine,
F Balkwill, and R Osborne, and F Burke, and S Naylor, and D Talbot, and H Durbin, and J Tavernier, and W Fiers
February 1991, The Journal of the Association of Physicians of India,
F Balkwill, and R Osborne, and F Burke, and S Naylor, and D Talbot, and H Durbin, and J Tavernier, and W Fiers
January 1985, Nature,
F Balkwill, and R Osborne, and F Burke, and S Naylor, and D Talbot, and H Durbin, and J Tavernier, and W Fiers
August 1987, Clinical physiology (Oxford, England),
Copied contents to your clipboard!